Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04505917
Other study ID # aswu/352/4/19
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2020
Est. completion date August 30, 2021

Study information

Verified date August 2020
Source Aswan University Hospital
Contact hany f Sallam, md
Phone +20102435461
Email hany.farouk@aswu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the effect of vaginal dinoprostone versus vaginal misoprostol administered before the copper intrauterine device(IUD) insertion in reducing IUD insertion pain and the difficulty in inserting the IUD in multiparous overweight and obese women


Description:

Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women. However, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use. Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date August 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- multi parous women requesting copper IUD insertion

- body mass index more than 25

Exclusion Criteria:

- pregnancy,

- null parous women,

- contraindications or allergy to dinoprostone or misoprostol,contraindication to IUD insertion,

- untreated active cervicitis or vaginitis,

- undiagnosed abnormal uterine bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dinoprostol
2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
misoprostol
2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
placebo
2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion

Locations

Country Name City State
Egypt Aswan University Hospital Aswan

Sponsors (1)

Lead Sponsor Collaborator
Aswan University Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in visual analog scale pain scores during intrauterine device insertion The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10 10 minuts
Secondary Intensity of pain: visual analogue scale Pain intensity will be assessed by visual analogue scale 30 minutes after the procedure.visual analogue scale ranging from 0 to 10 30 minutes after the procedure
Secondary the difference in visual analog scale pain scores during tenaculum application The difference in pain scores during tenaculum application using a visual analog scale from 0 to 10 10 minutes
Secondary the ease of IUD insertion the ease of IUD insertion using ease of insertion score from 0 to 10 cm (0 = very easy insertion, 10 cm = terribly difficult insertion) 10 minutes
Secondary women's satisfaction level: score women's satisfaction level using satisfaction score from 0 to 10 cm where 0 denotes no satisfaction and 10 denotes maximum satisfaction 10 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT04517890 - Transdermal Lidocaine Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System N/A
Completed NCT04505657 - Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography N/A
Not yet recruiting NCT04500002 - Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion N/A
Not yet recruiting NCT04505943 - Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion N/A
Completed NCT04500015 - Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion Phase 4
Completed NCT04499989 - Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion Phase 4
Completed NCT04500028 - Vaginal Isonicotinic Acid Hydrazide Administration Prior to Insertion Levonorgestrel-releasing Intrauterine System Phase 4